Detalles de la búsqueda
1.
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.
Future Oncol;
18(8): 903-913, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35073733
2.
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.
Future Oncol;
17(2): 137-149, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32938232
3.
A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris® ) in healthy male subjects.
Eur J Haematol;
105(1): 66-74, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32196749
4.
Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
Br J Clin Pharmacol;
83(4): 846-854, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27859472
5.
Repeatability of hypoxia PET imaging using [¹8F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial.
Eur J Nucl Med Mol Imaging;
42(12): 1840-9, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26136164
6.
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Eur Urol;
82(4): 365-373, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35643589
7.
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
J Immunother Cancer;
10(4)2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35444058
8.
Washout of 8²Rb as a marker of impaired tissue integrity, obtained by list-mode cardiac PET/CT: relationship with perfusion/metabolism patterns of myocardial viability.
Eur J Nucl Med Mol Imaging;
38(8): 1507-15, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21528386
9.
Longevity of Polymer-Infiltrated Ceramic Network and Zirconia-Reinforced Lithium Silicate Restorations: A Systematic Review and Meta-Analysis.
Materials (Basel);
14(17)2021 Sep 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34501148
10.
Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection.
J Exp Med;
197(12): 1645-55, 2003 Jun 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-12810686
11.
Ubiquitin-independent degradation of hepatitis C virus F protein.
J Virol;
83(2): 612-21, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18971267
12.
Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis.
Clin Rheumatol;
39(11): 3527, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32965602
13.
Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis.
Clin Rheumatol;
39(11): 3341-3352, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32876780
14.
A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis.
Clin Pharmacol Drug Dev;
9(8): 1003-1014, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32627420
15.
Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product.
Target Oncol;
15(6): 807, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33180232
16.
Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product.
Target Oncol;
15(5): 599-611, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33044684
17.
Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5.
J Virol;
82(15): 7492-503, 2008 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-18508900
18.
Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians.
Adv Ther;
33(12): 2160-2172, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27798772
19.
Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.
J Clin Pharmacol;
56(11): 1335-1343, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-26953185
20.
Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.
J Clin Pharmacol;
56(11): 1355-1361, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27029823